Sanofi is reported to be preparing a move to take control of US biotech Ocular Therapeutix, after an initial bid was rejected last year. That is according to French newspaper La Lettre, which said ...

Oct 10 (Reuters) - Drugmaker Bristol Myers Squibb (BMY.N), opens new tab said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash, aiming to ...

Drugmaker Bristol-Myers Squibb said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash, aiming to diversify from legacy products facing ...

The stars have aligned for Bristol Myers Squibb and Orbital Therapeutics. Pushing deeper into in vivo cell therapies, BMS has agreed to pay $1.5 billion to buy the biotech for a pipeline led by a ...

Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases Transaction further ...

Eight years after Novartis AG gained U.S. FDA approval of the first CAR T therapy, Kymriah (tisagenlecleucel), for B-cell acute lymphoblastic leukemia, developers are advancing prospects that could ...

IoCDB Share project repository, a CTI platform that collects data from VirusTotal, AlienVault OTX, PolySwarm and AbuseIPDB APIs for hashes, domains and IPs. AegisFlow is a threat-aware CI/CD pipeline ...

College Football CFB - Texas Longhorns vs. Ohio State Buckeyes - 08/30/2025 Ohio State Buckeyes Texas Longhorns BIG NOON KICKOFF ...

A smartphone-based digital therapeutic application designed to deliver suicide-focused cognitive-behavioral therapy (CBT) was associated with a sustained reduction in suicidal ideation through 24 ...